Sotorasib vs. Durvalumab for KRAS G12C Mutant Locally Advanced Non-small Cell Lung Cancer with Minimal Residual Disease

This study focuses on patients with a type of lung cancer called non-small cell lung cancer that is locally advanced and has a specific mutation known as KRAS G12C. These patients are either about to start, are currently undergoing, or have just finished a combination of chemotherapy and radiation therapy. The study aims to determine whether switching to a medication called sotorasib is more effective than continuing with a treatment called durvalumab for patients who still have traces of cancer DNA in their blood after the initial treatment. This is important because finding a more effective treatment could potentially improve survival rates and outcomes for these patients. Participants in this study will first complete standard treatments as planned, which include chemotherapy and radiation therapy. If traces of cancer DNA are still detectable in their blood after these initial treatments and their cancer has not progressed, they will continue with durvalumab treatment. During this period, blood tests will measure any remaining cancer DNA. Those who still show traces of cancer DNA will be randomly assigned to either continue with durvalumab or switch to taking sotorasib pills daily. The study will monitor how long patients live without their cancer worsening to evaluate the effectiveness of each treatment. Patients switching to sotorasib will first stop durvalumab for 28 days before starting the new medication. The study aims to provide insights into which treatment option better prevents cancer from progressing.